Dr Sade Mokuolu, group compliance manager, Watson-Marlow Fluid Technology Group, examines the importance of risk assessment in qualifying SU components to ensure global adoption continues at an accelerated pace.
The increased market value and small batch sizes of biologics has led to a boom in the employment of single use (SU) components for manufacturing therapeutics. The prevalence of these technologies within biopharmaceutical manufacturing has been widely disclosed.1